Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955524 | 0.81 | AR (1.00) | ARPARP1PRMT5LMNAHTT | |
| SCHEMBL12955359 | 0.81 | AR (1.00) | ARPARP1PRMT5LMNAHTT | |
| SCHEMBL12955377 | 0.81 | AR (0.68) | ARPARP1PRMT5LMNAHTT | |
| SCHEMBL25649870 | 0.81 | AR (0.68) | ARPARP1PRMT5LMNAHTT | |
| SCHEMBL12955341 | 0.78 | AR (0.77) | ARPARP1PRMT5LMNATSHR | |
| SCHEMBL28018259 | 0.78 | AR (0.63) | ARPARP1PRMT5LMNAHTT | |
| SCHEMBL1076493 | 0.78 | AR (1.00) | ARPARP1PRMT5LMNAHTT | |
| Hydrochloric Acid SCHEMBL30088838 | 0.77 | AR (0.74) | ARPARP1PRMT5LMNATSHR | |
| SCHEMBL863462 | 0.77 | AR (1.00) | ARPARP1PRMT5LMNATSHR | |
| SCHEMBL23571868 | 0.77 | AR (0.74) | ARPARP1PRMT5LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330442-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-01-19 | — | — | EP | disclosed |
| US-7750006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7151102-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20060142293-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1330442-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142293-A1 | Phthalazinone derivatives | CBR1, CBR3, PARP2 | AR 267/4885PARP1 5/4885PRMT5 1304/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | AR 435/4885PARP1 1/4885PRMT5 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.